ViroPharma (VPHM) Receives NoC from HealthCanada Cinryze NDA

ViroPharma Incorporated (Nasdaq: VPHM) announced that Health Canada has granted a Notice of Compliance (NOC) and approved a New Drug Submission (NDS) for Cinryze™ (C1 inhibitor [human]). Approval of Cinryze was granted for routine prevention of angioedema attacks in adult and adolescents with hereditary angioedema (HAE). Until now, there have been no approved plasma derived C1 inhibitor therapies for routine prevention of HAE attacks in Canada. ViroPharma's Canadian headquarters are located in Oakville, Ontario. We anticipate Cinryze to be commercially available in Canada as early as the second quarter of 2013.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• PMV Pharmaceuticals reports 46% response rate in ovarian cancer trial
• Ares closes Japan logistics fund at ¥612 billion hard cap
• NIO delivers 35,836 vehicles in August, up 14.5% year-over-year